Shaun Bagai is the CEO of RenovoRx, a life sciences company developing innovative targeted oncology therapies and commercializing RenovoCath, a novel, FDA-cleared local drug-delivery device, targeting high unmet medical needs.
RenovoRx’s patented Trans-Arterial Micro-Perfusion (TAMP) therapy platform, enabled by RenovoCath, is designed for targeted therapeutic delivery across the arterial wall near the tumor site to bathe the target tumor, while potentially minimizing the therapy’s toxicities versus systemic intravenous therapy.